Abstract:Background: The lymphatic system is crucial in maintaining the body fluid homeostasis. A dysfunctional lymphatic system may contribute to the refractoriness of ascites and edema in cirrhosis patients. Therefore, assessment of lymphatic dysfunction in cirrhosis patients with refractory ascites (RA) can be crucial as it would call for using different strategies for fluid mobilization. Aim: To assessing the magnitude, spectrum, and clinical associations of lymphatic dysfunction in liver cirrhosis patients with RA. Methods: This observational study included 155 consecutive cirrhosis patients with RA. The presence of clinical signs of lymphedema, such as peau d'orange appearance and positive Stemmer sign, intestinal lymphangiectasia (IL) on duodenal biopsy seen as dilated vessels in the lamina propria with strong D2-40 immunohistochemistry, and chylous ascites were used to diagnose the overt lymphatic dysfunctions. Results: A total of 69 (44.5%) patients out of 155 had evidence of lymphatic dysfunction. Peripheral lymphedema, found in 52 (33.5%) patients, was the most common manifestation, followed by IL in 42 (27.0%) patients, and chylous ascites in 2 (1.9%) patients. Compared to patients without lymphedema, those with lymphedema had higher mean age, median model for end-stage liver disease scores, mean body mass index, mean ascitic fluid triglyceride levels, and proportion of patients with hypoproteinemia (serum total protein < 5 g/dL) and lymphocytopenia (< 15% of total leukocyte count). Patients with IL also had a higher prevalence of lymphocytopenia and hypoproteinemia (28.6% vs. 9.1%, P = 0.004). Seven (13%) patients with lymphedema had lower limb cellulitis compared to none in those without it. On multivariate regression analysis, factors independently associated with lymphatic dysfunction included obesity [odds ratio (OR): 4.2, 95% confidence intervals (95%CI): 1.1-15.2, P = 0.027], lymphocytopenia [OR: 6.2, 95%CI: 2.9-13.2, P < 0.001], and hypoproteinemia [OR: 3.7, 95%CI: 1.5-8.82, P = 0.003]. Conclusion: Lymphatic dysfunction is common in cirrhosis patients with RA. Significant indicators of its presence include hypoproteinemia and lymphocytopenia, which are likely due to the loss of lymphatic fluid from the circulation. Future efforts to mobilize fluid in these patients should focus on methods to improve lymphatic drainage.

Two Unusual but Treatable Causes of Refractory Ascites After Liver Transplantation

An update on the pathogenesis and clinical management of cirrhosis with refractory ascites

Systematic sequential therapy for <i>ex vivo</i> liver resection and autotransplantation: A case report and review of literature

Constrictive pericarditis as a cause of refractory ascites after liver transplantation: A case report

The incidence and natural history of ascites after liver transplantation

[Update on Tolvaptan for the Treatment of Refractory Ascites in Liver Cirrhosis]

S4532 Idiopathic Refractory Ascites: A Rare and Fatal Complication of Haemopoietic Stem Cell Transplant in a Patient With Acute Myelogenous Leukemia

Management of refractory cirrhotic ascites: challenges and solutions

Treatment of Obstructive Jaundice Caused by Hepatic Artery Pseudoaneurysm after Liver Transplantation A Case Report

Current management of refractory ascites in patients with cirrhosis

Successful treatment of refractory ascites in a patient with liver cirrhosis combined with hepatic artery-portal vein malformation: A case report

Pharmacological Interventions for Cirrhotic Ascites: From Challenges to Emerging Therapeutic Horizons

Proximal Splenic Artery Embolization for Refractory Ascites and Hydrothorax Post-Liver Transplant

Successful Interventional Therapy for Portal Vein Stenosis after Ex Vivo Liver Resection and Autotransplantation in End-Stage Hepatic Alveolar Echinococcosis with Cavernous Transformation

Prevalence and risk factors of lymphatic dysfunction in cirrhosis patients with refractory ascites: An often unconsidered mechanism

Ascites, refractory ascites and hyponatremia in cirrhosis

Efficacy and safety of splenic artery embolization for intractable ascites using Amplatzer vascular plug versus coil after living donor liver transplantation

Ex Vivo Liver Resection and Auto-Transplantation As an Alternative for the Treatment of Liver Malignancies: Progress and Challenges.

Innovative approaches to the management of ascites in cirrhosis

Effect of ascites ultrafiltration-concentration back-transfusion treatment on the natural killer cells (NKT) and renal-angiotensin II-aldosterone system (RAAS) for patients with cirrhotic refractory ascites

Prolonged Anhepatic State as a Bridge to Retransplantation: A Challenging Case of a 35-Year-Old Male Liver Transplant Patient with a Temporary Portacaval Shunt